Conducted at 19 hospitals, the study included 167 patients that had not responded to at least one antiarrhythmic drug prior. Catheter ablation was administered to 106 of the patients, with the remaining 61 receiving different ADT.
After nine months, 66 percent of patients treated with catheter ablation were free from symptomatic AF, compared to only 16 percent that received additional ADT. A higher mean quality of life also was also seen in patients receiving the procedure.
The study, published by the Journal of the American Medical Association, was one of the most comprehensive clinical trials of the procedure as it is currently practiced.